Clinical characteristics
| Longer MMF | Shorter MMF | P value | |
| Subjects, n | 85 | 85 | – |
| Age, years | 34 (18–59) | 31 (18–60) | 0.083 |
| Gender, n (%) | 0.439 | ||
| Male | 51 (60) | 46 (54) | |
| Female | 34 (40) | 39 (46) | |
| Diagnosis, n (%) | 0.633 | ||
| AML | 34 (40) | 32 (38) | |
| ALL | 35 (41) | 33 (39) | |
| MDS | 13 (15) | 13 (15) | |
| Others | 3 (4) | 7 (8) | |
| Donor type | Related donors | Related donors | – |
| Stem cell source | BM+PB | BM+PB | – |
| Mismatch of HLA loci at A, B, DR, n (%) | 0.141 | ||
| 1/6 | 1 (1) | 3 (4) | |
| 1/3 | 16 (19) | 8 (9) | |
| 1/2 | 68 (80) | 74 (87) | |
| MNC in grafts,108/kg | 8 (6–13) | 8 (3–12) | 0.097 |
| CD34+ cells in grafts,106/kg | 3 (1–7) | 2 (1–7) | 0.106 |
| Conditioning regimen | BU+CY+ATG | BU+CY+ATG | – |
| GVHD prophylaxis | CSA+MMF+MTX | CSA+MMF+MTX | – |
| MMF duration, days | 41 (24–69) | 25 (15–36) | <0.001 |
| EBV serology, n (%) | 0.172 | ||
| D+/R+ | 70 (82) | 78 (92) | |
| D+/R− | 8 (9) | 3 (4) | |
| D−/R+ | 7 (8) | 4 (5) | |
| D−/R− | 0 | 0 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BM, bone marrow; BU, busulfan; CSA, cyclosporine A; CY, cyclophosphamide; EBV, Epstein-Barr virus; GVHD, graft-versus-host disease; MDS, myelodysplastic syndrome ; MMF, mycophenolate mofetil; MNC, mononuclear cells; MTX, methotrexate; PB, peripheral blood.